抄録
We comparatively assessed the overall efficacies of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy for previously untreated, EGFR mutation-positive, advanced non-small cell lung cancer in Asians through a meta-analysis of relevant phase-3 trials. The primary and secondary outcomes were overall survival (OS) and progression-free survival (PFS), respectively. Pooled estimates were calculated as hazard ratios (HRs) with 95% confidence intervals (CIs). Seven studies on EGFR-TKIs met the inclusion criteria for this study. The HRs and 95% CIs for OS and PFS for EGFR-TKIs, relative to chemotherapy, were 0.98 (0.77–1.24) and 0.32 (0.24–0.43), respectively. We found no difference in overall efficacy between EGFR-TKIs and chemotherapy in terms of OS, although the median PFS with EGFR-TKI was superior to that with chemotherapy among Asians with previously untreated, EGFR mutation-positive, advanced non-small cell lung cancer (UMIN ID: UMIN28424).
